<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02416193</url>
  </required_header>
  <id_info>
    <org_study_id>206988</org_study_id>
    <secondary_id>206988031815</secondary_id>
    <nct_id>NCT02416193</nct_id>
  </id_info>
  <brief_title>Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D)</brief_title>
  <acronym>THINK-D</acronym>
  <official_title>Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Loyola University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes increases the risk of cognitive dysfunction. The incidence of dementia is 1.5 to 2.5
      times higher in persons with diabetes than the general population. There is evidence that
      cognitive decline significantly impacts the ability to self-manage diabetes. Strategies to
      prevent cognitive decline in persons with diabetes has not been well studied. A recent study
      reported that in persons who had vitamin D deficiency, the risk for all-cause dementia and
      Alzheimer's was doubled. Vitamin D receptors are located in the brain and deficiency of
      vitamin D has been reported to negatively affect the development of brain. Therefore,
      providing vitamin D supplementation to improve cognitive function is worthy of study. The
      investigators propose a small, randomized controlled trial to determine the effects of
      vitamin D3 supplementation in persons with type 2 diabetes who have symptoms of cognitive
      impairment. Persons will be randomized to receive either weekly vitamin D3 supplementation
      (50,000 IUs) or a matching comparator (5000 IUs) for a period of three months. The study aims
      are to determine (1) the effect of vitamin D3 supplementation on cognitive function and (2)
      the effect of vitamin D3 supplementation on diabetes self-management. A sample of persons
      with type 2 diabetes (n=62), who have a subjective complaint of a cognitive dysfunction or
      scoring at least one standard deviation below normal on a cognitive functioning screening
      test, have vitamin D levels less 30 ng/ml, are not depressed (as this impacts cognitive
      function), and do not have severe diabetes complication will be recruited. Participants will
      be phone screened and complete two baseline visits prior to randomization. They will then
      have phone call and follow-up visits to assess (1) cognitive function using standardized
      tests to assess for executive function (2) serum measurements (HBA1c, fasting glucose,
      vitamin D levels, and cardiometabolic profile) and (3) surveys to assess cognitive function
      as well as self-management behaviors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Aims Diabetes increases the risk of cognitive dysfunction. The incidence of dementia is
      1.5 to 2.5 times higher in persons with diabetes than the general population (1). There is
      evidence that cognitive decline significantly impacts the ability to self-manage diabetes
      (2). Strategies to prevent cognitive decline in persons with diabetes has not been well
      studied. A recent study reported that in persons who had vitamin D deficiency, the risk for
      all-cause dementia and Alzheimer's was doubled (3). Vitamin D receptors are located in the
      brain, and deficiency of vitamin D has been reported to negatively affect the development of
      brain and impact both growth factor signaling and neural activity (4, 5). Therefore,
      providing vitamin D supplementation to improve cognitive function in persons with diabetes
      who are at great risk for this comorbid condition is important. The investigators propose a
      small, randomized controlled trial to determine the effects of vitamin D3 supplementation in
      persons with type 2 diabetes who have symptoms of cognitive impairment. Persons will be
      randomized to receive either weekly vitamin D3 supplementation (50,000 IUs) or a matching
      comparator (5000 IUs) for a period of three months.

      Primary Aim: To determine the effect of vitamin D3 supplementation on cognitive function for
      persons with type 2 diabetes.

      Primary Hypothesis: Persons receiving weekly vitamin D3 supplementation (50,000 IUs) will
      have improved cognitive function compared to those receiving the comparator (5000 IUs) at
      three months.

      Secondary Aim: To determine the effect of vitamin D3 supplementation on diabetes
      self-management.

      Secondary Hypothesis: Persons receiving weekly vitamin D3 supplementation (50,000 IUs) will
      have improved self-management compared to those receiving the comparator (5000 IUs) at three
      months.

      The importance of this study is several fold. Vitamin D supplementation is a low cost
      intervention (6), it has minimal side effects (7), and it could have high impact for persons
      with type 2 diabetes who suffer from cognitive impairment which can significantly affect
      their diabetes self-management.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive functioning</measure>
    <time_frame>13 weeks</time_frame>
    <description>Evaluate whether persons receiving weekly vitamin D3 supplementation (50,000 IUs) will have improved cognitive function as measured by a linear composite score on six cognitive functioning measures compared to those receiving the comparator (5000 IUs) at 13 weeks. The linear composite score will be calculated from performance on the following six cognitive functioning measures: (1) The Controlled Oral Word Association Test; (2) The Animal Naming Test; (3) The Letter Number Sequencing Test; (4) Stroop Interference Test; (5) Digit Symbol Modalities Test; and (6) Trail Making Test Parts A and B.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diabetes self-management</measure>
    <time_frame>13 weeks</time_frame>
    <description>Will evaluate whether persons receiving weekly vitamin D3 supplementation (50,000 IUs) will have improved self-management as measured by a linear composite score on five functioning measures compared to those receiving the comparator (5000 IUs) at 13 weeks. The linear composite score will be calculated from performance on the following five functioning measures: (1) The Pittsburg Sleep Quality Index; (2) The Perceived Stressor Scale; (3) Social Adjustment Scale Self-Report; (4) Godin Leisure Time Exercise Questionnaire; and (5) Endicott Work Productivity Scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes</condition>
  <condition>Executive Dysfunction</condition>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50,000 IU cholecalciferol once weekly for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5,000 IU cholecalciferol once weekly for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Participants will take randomly assigned high dose cholecalciferol once weekly for three months</description>
    <arm_group_label>High Dose</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Participants will take randomly assigned active comparator cholecalciferol once weekly for three months</description>
    <arm_group_label>Low Dose</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women and men aged 18 to 75 years

          -  Have type 2 diabetes

          -  Having a subjective complaint of a cognitive dysfunction or scoring at least one
             standard deviation below normal on a cognitive functioning screening test

          -  Vitamin D level as measured by 25-hydroxyvitamin D (25-OH D) &lt; 32 ng/mL

          -  Under the care of a healthcare provider

          -  Systolic blood pressure ≤160 and diastolic blood pressure ≤100

        Exclusion Criteria:

          -  Persons with malabsorption problems (e.g., crohn's disease)

          -  Hypercalcemia

          -  Supplementation other than a daily multivitamin

          -  Severe complications of diabetes (i.e., amputation, blindness, and dialysis)

          -  Concomitant use of steroids

          -  GFR &lt; 60

          -  Creatinine &gt; 1.2

          -  Significant depressive symptoms

          -  Having a history of bipolar depression, psychotic disorders, loss of consciousness
             greater than 5 minutes, or a current alcohol or substance use disorder

          -  Other serious medical conditions deemed significant by the PI or medical monitor

          -  Concomitant use of cholinesterase inhibitors

          -  Concomitant use of anxiolytics, kava kava, St. John's Wort, or Ginkgo Biloba

          -  Pregnancy

          -  HbA1c &gt;13%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary A Byrn, Ph.D., R.N.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary A Byrn, Ph.D., R.N.</last_name>
    <phone>773-508-3249</phone>
    <email>mbyrn@luc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>William H Adams, M.A.</last_name>
    <phone>708-216-6039</phone>
    <email>wadams@luc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary A Byrn, Ph.D., R.N.</last_name>
      <phone>773-508-3249</phone>
      <email>mbyrn@luc.edu</email>
    </contact>
    <investigator>
      <last_name>Mary A Byrn, Ph.D., R.N.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sue Penckofer, Ph.D., R.N.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William H Adams, M.A.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lee JH, Choi Y, Jun C, Hong YS, Cho HB, Kim JE, Lyoo IK. Neurocognitive changes and their neural correlates in patients with type 2 diabetes mellitus. Endocrinol Metab (Seoul). 2014 Jun;29(2):112-21. doi: 10.3803/EnM.2014.29.2.112. Review.</citation>
    <PMID>25031883</PMID>
  </reference>
  <reference>
    <citation>Smith MA, Else JE, Paul L, Foster JK, Walker M, Wesnes KA, Riby LM. Functional Living in Older Adults With Type 2 Diabetes: Executive Functioning, Dual Task Performance, and the Impact on Postural Stability and Motor Control. J Aging Health. 2014 Aug;26(5):841-859. Epub 2014 Jun 4.</citation>
    <PMID>24898849</PMID>
  </reference>
  <reference>
    <citation>Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PH, Fried L, Kestenbaum BR, Kuller LH, Langa KM, Lopez OL, Kos K, Soni M, Llewellyn DJ. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014 Sep 2;83(10):920-8. doi: 10.1212/WNL.0000000000000755. Epub 2014 Aug 6.</citation>
    <PMID>25098535</PMID>
  </reference>
  <reference>
    <citation>McCann JC, Ames BN. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J. 2008 Apr;22(4):982-1001. Epub 2007 Dec 4. Review.</citation>
    <PMID>18056830</PMID>
  </reference>
  <reference>
    <citation>Schlögl M, Holick MF. Vitamin D and neurocognitive function. Clin Interv Aging. 2014 Apr 2;9:559-68. doi: 10.2147/CIA.S51785. eCollection 2014. Review.</citation>
    <PMID>24729696</PMID>
  </reference>
  <reference>
    <citation>Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006 Mar;81(3):353-73. Review.</citation>
    <PMID>16529140</PMID>
  </reference>
  <reference>
    <citation>Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266-81. Review.</citation>
    <PMID>17634462</PMID>
  </reference>
  <reference>
    <citation>Tuligenga RH, Dugravot A, Tabák AG, Elbaz A, Brunner EJ, Kivimäki M, Singh-Manoux A. Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study. Lancet Diabetes Endocrinol. 2014 Mar;2(3):228-35. doi: 10.1016/S2213-8587(13)70192-X. Epub 2013 Dec 19.</citation>
    <PMID>24622753</PMID>
  </reference>
  <reference>
    <citation>Wennberg AM, Gottesman RF, Kaufmann CN, Albert MS, Chen-Edinboro LP, Rebok GW, Kasper JD, Spira AP. Diabetes and cognitive outcomes in a nationally representative sample: the National Health and Aging Trends Study. Int Psychogeriatr. 2014 Oct;26(10):1729-35. doi: 10.1017/S1041610214001380. Epub 2014 Jul 30.</citation>
    <PMID>25075535</PMID>
  </reference>
  <reference>
    <citation>Munshi MN, Hayes M, Iwata I, Lee Y, Weinger K. Which aspects of executive dysfunction influence ability to manage diabetes in older adults? Diabet Med. 2012 Sep;29(9):1171-7. doi: 10.1111/j.1464-5491.2012.03606.x.</citation>
    <PMID>22340082</PMID>
  </reference>
  <reference>
    <citation>Grober E, Hall CB, Hahn SR, Lipton RB. Memory Impairment and Executive Dysfunction are Associated with Inadequately Controlled Diabetes in Older Adults. J Prim Care Community Health. 2011 Oct 1;2(4):229-33. doi: 10.1177/2150131911409945. Epub 2011 Jun 1.</citation>
    <PMID>23804840</PMID>
  </reference>
  <reference>
    <citation>Retracted: Executive dysfunction in elderly diabetic patients. Geriatr Gerontol Int. 2015 Aug;15(8):1106. doi: 10.1111/ggi.12288. Epub 2014 Apr 21.</citation>
    <PMID>24750335</PMID>
  </reference>
  <reference>
    <citation>Winkler A, Dlugaj M, Weimar C, Jöckel KH, Erbel R, Dragano N, Moebus S. Association of diabetes mellitus and mild cognitive impairment in middle-aged men and women. J Alzheimers Dis. 2014;42(4):1269-77. doi: 10.3233/JAD-140696.</citation>
    <PMID>25024326</PMID>
  </reference>
  <reference>
    <citation>Geijselaers SLC, Sep SJS, Stehouwer CDA, Biessels GJ. Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review. Lancet Diabetes Endocrinol. 2015 Jan;3(1):75-89. doi: 10.1016/S2213-8587(14)70148-2. Epub 2014 Aug 24. Review. Erratum in: Lancet Diabetes Endocrinol. 2015 Jan;3(1):e1.</citation>
    <PMID>25163604</PMID>
  </reference>
  <reference>
    <citation>Annweiler C, Montero-Odasso M, Llewellyn DJ, Richard-Devantoy S, Duque G, Beauchet O. Meta-analysis of memory and executive dysfunctions in relation to vitamin D. J Alzheimers Dis. 2013;37(1):147-71. doi: 10.3233/JAD-130452. Review.</citation>
    <PMID>23948884</PMID>
  </reference>
  <reference>
    <citation>Penckofer S, Kouba J, Wallis DE, Emanuele MA. Vitamin D and diabetes: let the sunshine in. Diabetes Educ. 2008 Nov-Dec;34(6):939-40, 942, 944 passim. doi: 10.1177/0145721708326764. Review.</citation>
    <PMID>19075078</PMID>
  </reference>
  <reference>
    <citation>Gulseth HL, Gjelstad IM, Tierney AC, Lovegrove JA, Defoort C, Blaak EE, Lopez-Miranda J, Kiec-Wilk B, Risérus U, Roche HM, Drevon CA, Birkeland KI. Serum vitamin D concentration does not predict insulin action or secretion in European subjects with the metabolic syndrome. Diabetes Care. 2010 Apr;33(4):923-5. doi: 10.2337/dc09-1692. Epub 2010 Jan 12. Erratum in: Diabetes Care. 2010 Dec;33(12):2725. Ris, Ulférus [corrected to Risérus, Ulf].</citation>
    <PMID>20067973</PMID>
  </reference>
  <reference>
    <citation>Davidson MB, Duran P, Lee ML, Friedman TC. High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care. 2013 Feb;36(2):260-6. doi: 10.2337/dc12-1204. Epub 2012 Oct 1.</citation>
    <PMID>23033239</PMID>
  </reference>
  <reference>
    <citation>Penckofer S, Kouba J, Byrn M, Estwing Ferrans C. Vitamin D and depression: where is all the sunshine? Issues Ment Health Nurs. 2010 Jun;31(6):385-93. doi: 10.3109/01612840903437657.</citation>
    <PMID>20450340</PMID>
  </reference>
  <reference>
    <citation>Drechsler C, Schmiedeke B, Niemann M, Schmiedeke D, Krämer J, Turkin I, Blouin K, Emmert A, Pilz S, Obermayer-Pietsch B, Weidemann F, Breunig F, Wanner C. Potential role of vitamin D deficiency on Fabry cardiomyopathy. J Inherit Metab Dis. 2014 Mar;37(2):289-95. doi: 10.1007/s10545-013-9653-8. Epub 2013 Oct 19.</citation>
    <PMID>24141790</PMID>
  </reference>
  <reference>
    <citation>Alves MR, Yamamoto T, Arias-Carrión O, Rocha NB, Nardi AE, Machado S, Silva AC. Executive function impairments in patients with depression. CNS Neurol Disord Drug Targets. 2014;13(6):1026-40. Review.</citation>
    <PMID>24923347</PMID>
  </reference>
  <reference>
    <citation>Zahodne LB, Nowinski CJ, Gershon RC, Manly JJ. Depressive symptoms are more strongly related to executive functioning and episodic memory among African American compared with non-Hispanic White older adults. Arch Clin Neuropsychol. 2014 Nov;29(7):663-9. doi: 10.1093/arclin/acu045. Epub 2014 Oct 3.</citation>
    <PMID>25280795</PMID>
  </reference>
  <reference>
    <citation>Jorde R, Sneve M, Figenschau Y, Svartberg J, Waterloo K. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Intern Med. 2008 Dec;264(6):599-609. doi: 10.1111/j.1365-2796.2008.02008.x. Epub 2008 Sep 10.</citation>
    <PMID>18793245</PMID>
  </reference>
  <reference>
    <citation>Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, Gagne D, D'Souza C, Ursell M, O'Connor P. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010 Jun 8;74(23):1852-9. doi: 10.1212/WNL.0b013e3181e1cec2. Epub 2010 Apr 28. Erratum in: Neurology. 2010 Aug 3;75(5):480. Neurology. 2010 Sep 14;75(11):1029. Dosage error in article text.</citation>
    <PMID>20427749</PMID>
  </reference>
  <reference>
    <citation>Nazarian S, St Peter JV, Boston RC, Jones SA, Mariash CN. Vitamin D3 supplementation improves insulin sensitivity in subjects with impaired fasting glucose. Transl Res. 2011 Nov;158(5):276-81. doi: 10.1016/j.trsl.2011.05.002. Epub 2011 Jun 7.</citation>
    <PMID>22005267</PMID>
  </reference>
  <reference>
    <citation>Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005 Jul;80(7):856-61.</citation>
    <PMID>16007889</PMID>
  </reference>
  <reference>
    <citation>Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. doi: 10.1210/jc.2011-0385. Epub 2011 Jun 6. Erratum in: J Clin Endocrinol Metab. 2011 Dec;96(12):3908.</citation>
    <PMID>21646368</PMID>
  </reference>
  <reference>
    <citation>Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr. 2011 Aug;94(2):486-94. doi: 10.3945/ajcn.111.011684. Epub 2011 Jun 29.</citation>
    <PMID>21715514</PMID>
  </reference>
  <reference>
    <citation>Koutkia P, Lu Z, Chen TC, Holick MF. Treatment of vitamin D deficiency due to Crohn's disease with tanning bed ultraviolet B radiation. Gastroenterology. 2001 Dec;121(6):1485-8.</citation>
    <PMID>11729127</PMID>
  </reference>
  <reference>
    <citation>Lips P. Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):611-4. Review.</citation>
    <PMID>15225848</PMID>
  </reference>
  <reference>
    <citation>Etgen T, Sander D, Bickel H, Sander K, Förstl H. Vitamin D deficiency, cognitive impairment and dementia: a systematic review and meta-analysis. Dement Geriatr Cogn Disord. 2012;33(5):297-305. doi: 10.1159/000339702. Epub 2012 Jul 2. Review.</citation>
    <PMID>22759681</PMID>
  </reference>
  <reference>
    <citation>Wallis DE, Penckofer S, Sizemore GW. The &quot;sunshine deficit&quot; and cardiovascular disease. Circulation. 2008 Sep 30;118(14):1476-85. doi: 10.1161/CIRCULATIONAHA.107.713339. Review. Erratum in: Circulation. 2009 Jun 2;119(21):e550.</citation>
    <PMID>18824654</PMID>
  </reference>
  <reference>
    <citation>Glanz K, Yaroch AL, Dancel M, Saraiya M, Crane LA, Buller DB, Manne S, O'Riordan DL, Heckman CJ, Hay J, Robinson JK. Measures of sun exposure and sun protection practices for behavioral and epidemiologic research. Arch Dermatol. 2008 Feb;144(2):217-22. doi: 10.1001/archdermatol.2007.46.</citation>
    <PMID>18283179</PMID>
  </reference>
  <reference>
    <citation>Cummings SR, Block G, McHenry K, Baron RB. Evaluation of two food frequency methods of measuring dietary calcium intake. Am J Epidemiol. 1987 Nov;126(5):796-802.</citation>
    <PMID>3661527</PMID>
  </reference>
  <reference>
    <citation>Welch G, Weinger K, Anderson B, Polonsky WH. Responsiveness of the Problem Areas In Diabetes (PAID) questionnaire. Diabet Med. 2003 Jan;20(1):69-72. Review.</citation>
    <PMID>12519323</PMID>
  </reference>
  <reference>
    <citation>Ruff RM, Light RH, Parker SB, Levin HS. Benton Controlled Oral Word Association Test: reliability and updated norms. Arch Clin Neuropsychol. 1996;11(4):329-38.</citation>
    <PMID>14588937</PMID>
  </reference>
  <reference>
    <citation>Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213.</citation>
    <PMID>2748771</PMID>
  </reference>
  <reference>
    <citation>Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983 Dec;24(4):385-96.</citation>
    <PMID>6668417</PMID>
  </reference>
  <reference>
    <citation>Gameroff MJ, Wickramaratne P, Weissman MM. Testing the Short and Screener versions of the Social Adjustment Scale-Self-report (SAS-SR). Int J Methods Psychiatr Res. 2012 Mar;21(1):52-65. doi: 10.1002/mpr.358. Epub 2011 Dec 5.</citation>
    <PMID>22139969</PMID>
  </reference>
  <reference>
    <citation>Endicott J, Nee J. Endicott Work Productivity Scale (EWPS): a new measure to assess treatment effects. Psychopharmacol Bull. 1997;33(1):13-6.</citation>
    <PMID>9133746</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2015</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loyola University</investigator_affiliation>
    <investigator_full_name>Mary A Byrn</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Cognition</keyword>
  <keyword>Functioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

